(Q43659958)

25 November 2017

Analysis of the cilostazol safety database (English)

1 reference

25 November 2017

C M Pratt

1

1 reference

PubMed ID

11434897

25 November 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

American Journal of Cardiology

25 November 2017

1 reference

25 November 2017

87

1 reference

25 November 2017

28D-33D

1 reference

25 November 2017

12A

1 reference

A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901719-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901719-2

Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901719-2

Mortality over a period of 10 years in patients with peripheral arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901719-2

Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901719-2

Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901719-2

Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901719-2

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901719-2

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901719-2

Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901719-2

Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901719-2

Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901719-2

10.1016/S0002-9149(01)01719-2

7 January 2021

Identifiers

DOI

1 reference

25 November 2017

1 reference

PubMed ID

11434897